This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ely, S. Articles by Chen-Kiang, S. Search for Related Content PubMed PubMed Citation Articles by Ely, S. Articles by Chen-Kiang, S.

Mutually Exclusive Cyclin-Dependent Kinase 4/Cyclin D1 and Cyclin-Dependent Kinase 6/Cyclin D2 Pairing Inactivates Retinoblastoma Protein and Promotes Cell Cycle Dysregulation in Multiple Myeloma

Departments of ¹ Pathology and Laboratory Medicine, ² Medicine, and ³ Orthopaedics and ⁴ Graduate Program in Immunology and Microbial Pathogenesis, Weill Medical College of Cornell University, New York, New York

Requests for reprints: Selina Chen-Kiang, Department of Pathology, Cornell University Medical College, 1300 York Avenue, C-338, New York, NY 10021. Phone: 212-746-6440; Fax: 212-746-7996; E-mail: sckiang{at}med.cornell.edu.

Multiple myeloma, the second most common hematopoietic cancer, ultimately becomes refractory to treatment when self-renewing multiple myeloma cells begin unrestrained proliferation by unknown mechanisms. Here, we show that one, but not more than one, of the three early G₁ D cyclins is elevated in each case of multiple myeloma. Cyclin D1 or D3 expression does not vary in the clinical course, but that alone is insufficient to promote cell cycle progression unless cyclin-dependent kinase 4 (cdk4) is also elevated, in the absence of cdk6, to phosphorylate the retinoblastoma protein (Rb). By contrast, cyclin D2 and cdk6 are coordinately increased, thereby overriding the inhibition by cdk inhibitors p18^INK4c and p27^Kip1 and phosphorylating Rb in conjunction with the existing cdk4. Thus, cyclin D1 pairs exclusively with cdk4 and cdk6 pairs only with cyclin D2, although cyclin D2 can also pair with cdk4 in multiple myeloma cells. The basis for this novel and specific cdk/D cyclin pairing lies in differential transcriptional activation. In addition, cyclin D1– or cyclin D3–expressing multiple myeloma cells are uniformly distributed in the bone marrow, whereas cdk6-specific phosphorylation of Rb occurs in discrete foci of bone marrow multiple myeloma cells before proliferation early in the clinical course and is then heightened with proliferation and disease progression. Mutually exclusive cdk4/cyclin D1 and cdk6/cyclin D2 pairing, therefore, is likely to be a critical determinant for cell cycle reentry and progression and may play a pivotal role in the expansion of self-renewing multiple myeloma cells. (Cancer Res 2005; 65(24): 11345-53)

This article has been cited by other articles:

				L. B. Baughn, M. Di Liberto, R. Niesvizky, H. J. Cho, D. Jayabalan, J. Lane, F. Liu, and S. Chen-Kiang CDK2 Phosphorylation of Smad2 Disrupts TGF-{beta} Transcriptional Regulation in Resistant Primary Bone Marrow Myeloma Cells J. Immunol., February 15, 2009; 182(4): 1810 - 1817. [Abstract] [Full Text] [PDF]

				P. E. Leone, B. A. Walker, M. W. Jenner, L. Chiecchio, G. Dagrada, R. K.M. Protheroe, D. C. Johnson, N. J. Dickens, J. L. Brito, M. Else, et al. Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications Clin. Cancer Res., October 1, 2008; 14(19): 6033 - 6041. [Abstract] [Full Text] [PDF]

				X. Mao, S.-b. Liang, R. Hurren, M. Gronda, S. Chow, G. W. Xu, X. Wang, R. B. Zavareh, N. Jamal, H. Messner, et al. Cyproheptadine displays preclinical activity in myeloma and leukemia Blood, August 1, 2008; 112(3): 760 - 769. [Abstract] [Full Text] [PDF]

				E. Menu, J. Garcia, X. Huang, M. Di Liberto, P. L. Toogood, I. Chen, K. Vanderkerken, and S. Chen-Kiang A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model Cancer Res., July 15, 2008; 68(14): 5519 - 5523. [Abstract] [Full Text] [PDF]

				Y. Peng, F. Chen, J. Melamed, L. Chiriboga, J. Wei, X. Kong, M. Mcleod, Y. Li, C. X. Li, A. Feng, et al. Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer PNAS, April 1, 2008; 105(13): 5236 - 5241. [Abstract] [Full Text] [PDF]

				L. B. Baughn, M. Di Liberto, K. Wu, P. Toogood, T. Louie, R. Gottschalk, R. Niesvizky, H. J. Cho, S. Ely, M. A.S. Moore, et al. A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cdk4/6. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 369 - 369. [Abstract] [PDF]

				F. Zhan, Y. Huang, S. Colla, J. P. Stewart, I. Hanamura, S. Gupta, J. Epstein, S. Yaccoby, J. Sawyer, B. Burington, et al. The molecular classification of multiple myeloma Blood, September 15, 2006; 108(6): 2020 - 2028. [Abstract] [Full Text] [PDF]

				L. B. Baughn, M. Di Liberto, K. Wu, P. L. Toogood, T. Louie, R. Gottschalk, R. Niesvizky, H. Cho, S. Ely, M. A.S. Moore, et al. A novel orally active small molecule potently induces g1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res., August 1, 2006; 66(15): 7661 - 7667. [Abstract] [Full Text] [PDF]